We prepare our consolidated financial statements in accordance with generally accepted accounting principles for the United States (GAAP). The non-GAAP financial measures, such as net income (loss) ...

SAINT PAUL, Minn.--(BUSINESS WIRE)--Aria CV, Inc, a developer of medical devices treating pulmonary hypertension, today announced the first patient was implanted with the Gen 2 Aria CV Pulmonary ...

SAN DIEGO, CA / ACCESS Newswire / May 12, 2026 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness ...

Repatha is the Only PCSK9 Inhibitor to Significantly Reduce the Risk of First CV Events in High-Risk Primary Prevention VESALIUS-CV Subgroup Findings Reinforce Benefit of Earlier Initiation of Repatha ...

With the eyes of the military firmly fixed on other tiltrotor aircraft currently being developed, one would have thought the existing V-22 Osprey is kind of on its way out the door. But that’s hardly ...

In patients with type 2 diabetes (T2D) without prior cardiovascular disease (CVD), heart failure (HF) accounted for 16.8% of first major CV events. The occurrence of HF was more strongly associated ...

(UPDATED) Swift initiation of rhythm-control therapy in patients with recently diagnosed atrial fibrillation in the setting of other cardiovascular conditions reduced the risk of CV events as compared ...

Please provide your email address to receive an email when new articles are posted on . Social isolation appeared to have little direct impact on the risk for developing a first cardiac event or ...

NEW ORLEANS -- Adding the PCSK9 inhibitor evolocumab (Repatha) to stable lipid-lowering therapy reduced major adverse cardiac events (MACE) in patients with atherosclerosis or high-risk diabetes, but ...